Enzalutamide d3

DB19123InvestigationalSmall molecule

Enzalutamide d3 is under investigation in clinical trial NCT03850795 (HC-1119 Versus Enzalutamide in Metastatic Castration-resistant Prostate Cancer (Mcrpc)).

Chemical structure of Enzalutamide d3
Formula / weight
C21H16F4N4O2S · 467.46 g/mol (avg)
Also known as
4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-n-(methyl-d3)benzamide · Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-n-(methyl-d3)- · DEUTENZALUTAMIDE
Code names
HC-1119

Resolves to

Compound
UNII3OKI556HC2CAS1443331-82-5ChEMBLCHEMBL4594421
Structure
InChIKeyWXCXUHSOUPDCQV-HPRDVNIFSA-NSMILES[2H]C([2H])([2H])NC(=O)C1=CC=C(C=C1F)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F
Targets
P10275AR

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Enzalutamide d3, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In